SCHEMBL2803190

SCHEMBL2803190

CCOC(=O)c1cnn2c(Nc3cc(C)ccc3C)c(C(=O)N3CCC4(CC3)COc3ccccc34)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 1/20 0.40
IDO1 P14902 1/20 0.38
KDM4E B2RXH2 6/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
HPGD P15428 6/20 0.37
KDR P35968 1/20 0.36
TP53 P04637 3/20 0.36
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NFKB1 P19838 2/20 0.35
NFKB2 Q00653 2/20 0.35
RELA Q04206 2/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 5/20 0.35
ALDH1A1 P00352 4/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
BRAF P15056 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2800216 0.93 AVPR1A (0.41) AVPR1AIDO1KDM4ENPC1RAB9A
SCHEMBL2800426 0.91 AVPR1A (0.41) AVPR1AIDO1KDM4ERAB9AHPGD
SCHEMBL2801683 0.91 KDM4E (0.36) IDO1KDM4ENPC1RAB9AHPGD
SCHEMBL2803317 0.90 KDR (0.44) AVPR1AIDO1KDM4ENPC1RAB9A
SCHEMBL2801052 0.90 ALDH1A1 (0.37) KDM4ENPC1RAB9AHPGDKDR
SCHEMBL2801064 0.89 AVPR1A (0.39) AVPR1AIDO1KDM4ENPC1RAB9A
SCHEMBL2803802 0.88 AVPR1A (0.37) AVPR1AIDO1KDM4EHPGDTP53
SCHEMBL2801628 0.87 HPGD (0.38) AVPR1AKDM4ENPC1RAB9AHPGD
SCHEMBL2803128 0.85 BRAF (0.37) KDM4ENPC1RAB9AHPGDKDR
SCHEMBL2802360 0.85 KDM4E (0.36) AVPR1AIDO1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 AVPR1A 4789/4885IDO1 2086/4885KDM4E 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.